|Brand name(s), other common name(s)||Iclusig®|
|Drug type||Tyrosine kinase inhibitor|
|How the drug is given||By mouth|
The FDA has asked the manufacturer of the leukemia chemotherapy drug Iclusig (ponatinib) to suspend marketing and sales of Iclusig because of the risk of life-threatening blood clots and severe narrowing of blood vessels. October 31, 2013. More Information, click here.
Iclusig is FDA approved to treat adult patients who have chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy, or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy.
Side effects needing medical attention:Hypertension; rash; abdominal pain; fatigue; dizziness; headache; cough; dry skin; constipation; joint pain; nausea; diarrhea; vomiting; fever; low platelets; low red blood cells; low neutrophils; low level of lymphocytes; low white blood cell count; cardiac failure; pneumonia; respiratory tract infection, urinary tract infection; peripheral neuropathy; back pain; muscle spasms; bone pain; fatigue.